Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date16 Apr 2019 |
评价百蕊颗粒治疗小儿急性上呼吸道感染(风热证)有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Bairui Granules in the treatment of acute upper respiratory tract infection (wind-heat syndrome) in children
评价百蕊颗粒治疗小儿急性上呼吸道感染(风热证)的有效性和安全性
[Translation] To evaluate the efficacy and safety of Bairui granules in the treatment of acute upper respiratory tract infection (wind-heat syndrome) in children
评价百蕊颗粒治疗小儿急性上呼吸道感染(风热证)有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Bairui Granule in the treatment of acute upper respiratory tract infection (wind-heat syndrome) in children
评价百蕊颗粒治疗小儿急性上呼吸道感染(风热证)的有效性和安全性
[Translation] To evaluate the efficacy and safety of Bairui granules in the treatment of acute upper respiratory tract infection (wind-heat syndrome) in children
百蕊颗粒治疗小儿急性上呼吸道感染(风热证)的有效性及安全性的随机、双盲、平行对照、多中心临床试验
[Translation] A randomized, double-blind, parallel-controlled, multicenter clinical trial on the efficacy and safety of Bairui Granule in the treatment of acute upper respiratory tract infection (wind-heat syndrome) in children
1.评价百蕊颗粒治疗小儿急性上呼吸道感染(风热证)的缩短病程作用和症状改善作用。 2.观察百蕊颗粒临床应用的安全性。
[Translation] 1. To evaluate the effect of Bairui Granule in shortening the course of disease and improving symptoms in treating acute upper respiratory tract infection (wind-heat syndrome) in children. 2. To observe the safety of Bairui Granule in clinical application.
100 Clinical Results associated with Anhui Jiuhua Huayuan Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Anhui Jiuhua Huayuan Pharmaceutical Co., Ltd.
100 Deals associated with Anhui Jiuhua Huayuan Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Anhui Jiuhua Huayuan Pharmaceutical Co., Ltd.